Insights into the cardiovascular benefits of taurine: a systematic review and meta-analysis.
Cardiac function
Heart failure
Hypertension
Nutrition
Taurine
Journal
Nutrition journal
ISSN: 1475-2891
Titre abrégé: Nutr J
Pays: England
ID NLM: 101152213
Informations de publication
Date de publication:
15 Aug 2024
15 Aug 2024
Historique:
received:
10
03
2024
accepted:
08
08
2024
medline:
16
8
2024
pubmed:
16
8
2024
entrez:
15
8
2024
Statut:
epublish
Résumé
Cardiovascular disease (CVD) remains the foremost cause of mortality globally. Taurine, an amino acid, holds promise for cardiovascular health through mechanisms such as calcium regulation, blood pressure reduction, and antioxidant and anti-inflammatory effects. Despite these potential benefits, previous studies have yielded inconsistent results. This meta-analysis of randomized controlled trials (RCTs) aims to evaluate the existing evidence on the quantitative effects of taurine on hemodynamic parameters and cardiac function grading, which are indicative of overall cardiovascular health and performance. We conducted an electronic search across multiple databases, including Embase, PubMed, Web of Science, Cochrane CENTRAL, and ClinicalTrials.gov, from their inception to January 2, 2024. Our analysis focused on key cardiovascular outcomes, such as heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular ejection fraction (LVEF), and New York Heart Association (NYHA) Functional Classification. Meta-regression was applied to explore dose-dependent relationships based on the total taurine dose administered during the treatment period. A subgroup analysis, stratified according to the baseline disease status of patients, was also conducted. The analysis included a pooled sample of 808 participants from 20 randomized controlled trials. Taurine demonstrated a significant reduction in HR (weighted mean difference [WMD] = -3.579 bpm, 95% confidence interval [CI] = -6.044 to -1.114, p = 0.004), SBP (WMD = -3.999 mm Hg, 95% CI = -7.293 to -0.706, p = 0.017), DBP (WMD: -1.435 mm Hg, 95% CI: -2.484 to -0.386, p = 0.007), NYHA (WMD: -0.403, 95% CI: -0.522 to -0.283, p < 0.001), and a significant increase in LVEF (WMD: 4.981%, 95% CI: 1.556 to 8.407, p = 0.004). Meta-regression indicated a dose-dependent reduction in HR (coefficient = -0.0150 per g, p = 0.333), SBP (coefficient = -0.0239 per g, p = 0.113), DBP (coefficient = -0.0089 per g, p = 0.110), and NYHA (coefficient = -0.0016 per g, p = 0.111), and a positive correlation with LVEF (coefficient = 0.0285 per g, p = 0.308). No significant adverse effects were observed compared to controls. In subgroup analysis, taurine significantly improved HR in heart failure patients and healthy individuals. Taurine significantly reduced SBP in healthy individuals, heart failure patients, and those with other diseases, while significantly lowered DBP in hypertensive patients It notably increased LVEF in heart failure patients and improved NYHA functional class in both heart failure patients and those with other diseases. Taurine showed noteworthy effects in preventing hypertension and enhancing cardiac function. Individuals prone to CVDs may find it advantageous to include taurine in their daily regimen.
Sections du résumé
BACKGROUND
BACKGROUND
Cardiovascular disease (CVD) remains the foremost cause of mortality globally. Taurine, an amino acid, holds promise for cardiovascular health through mechanisms such as calcium regulation, blood pressure reduction, and antioxidant and anti-inflammatory effects. Despite these potential benefits, previous studies have yielded inconsistent results. This meta-analysis of randomized controlled trials (RCTs) aims to evaluate the existing evidence on the quantitative effects of taurine on hemodynamic parameters and cardiac function grading, which are indicative of overall cardiovascular health and performance.
METHODS
METHODS
We conducted an electronic search across multiple databases, including Embase, PubMed, Web of Science, Cochrane CENTRAL, and ClinicalTrials.gov, from their inception to January 2, 2024. Our analysis focused on key cardiovascular outcomes, such as heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular ejection fraction (LVEF), and New York Heart Association (NYHA) Functional Classification. Meta-regression was applied to explore dose-dependent relationships based on the total taurine dose administered during the treatment period. A subgroup analysis, stratified according to the baseline disease status of patients, was also conducted.
RESULTS
RESULTS
The analysis included a pooled sample of 808 participants from 20 randomized controlled trials. Taurine demonstrated a significant reduction in HR (weighted mean difference [WMD] = -3.579 bpm, 95% confidence interval [CI] = -6.044 to -1.114, p = 0.004), SBP (WMD = -3.999 mm Hg, 95% CI = -7.293 to -0.706, p = 0.017), DBP (WMD: -1.435 mm Hg, 95% CI: -2.484 to -0.386, p = 0.007), NYHA (WMD: -0.403, 95% CI: -0.522 to -0.283, p < 0.001), and a significant increase in LVEF (WMD: 4.981%, 95% CI: 1.556 to 8.407, p = 0.004). Meta-regression indicated a dose-dependent reduction in HR (coefficient = -0.0150 per g, p = 0.333), SBP (coefficient = -0.0239 per g, p = 0.113), DBP (coefficient = -0.0089 per g, p = 0.110), and NYHA (coefficient = -0.0016 per g, p = 0.111), and a positive correlation with LVEF (coefficient = 0.0285 per g, p = 0.308). No significant adverse effects were observed compared to controls. In subgroup analysis, taurine significantly improved HR in heart failure patients and healthy individuals. Taurine significantly reduced SBP in healthy individuals, heart failure patients, and those with other diseases, while significantly lowered DBP in hypertensive patients It notably increased LVEF in heart failure patients and improved NYHA functional class in both heart failure patients and those with other diseases.
CONCLUSIONS
CONCLUSIONS
Taurine showed noteworthy effects in preventing hypertension and enhancing cardiac function. Individuals prone to CVDs may find it advantageous to include taurine in their daily regimen.
Identifiants
pubmed: 39148075
doi: 10.1186/s12937-024-00995-5
pii: 10.1186/s12937-024-00995-5
doi:
Substances chimiques
Taurine
1EQV5MLY3D
Types de publication
Journal Article
Systematic Review
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
93Subventions
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST 106-2314-B-002-180-MY3 and MOST 109-2314-B-002-114-MY3
Organisme : National Science and Technology, Taiwan
ID : NSTC 112-2314-B-002-134
Informations de copyright
© 2024. The Author(s).
Références
Cardiovascular diseases (CVDs) https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP, Commodore-Mensah Y, et al. Heart Disease and Stroke Statistics-2022 Update: a report from the American Heart Association. Circulation. 2022;145:e153–639.
pubmed: 35078371
doi: 10.1161/CIR.0000000000001052
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney M-T, Corrà U, Cosyns B, Deaton C, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–81.
pubmed: 27222591
pmcid: 4986030
doi: 10.1093/eurheartj/ehw106
Huxtable RJ. Physiological actions of taurine. Physiol Rev. 1992;72:101–63.
pubmed: 1731369
doi: 10.1152/physrev.1992.72.1.101
Schaffer SW, Jong CJ, Ramila KC, Azuma J. Physiological roles of taurine in heart and muscle. J Biomed Sci. 2010;17(Suppl 1):S2.
pubmed: 20804594
pmcid: 2994395
doi: 10.1186/1423-0127-17-S1-S2
Tzang CC, Chi LY, Lin LH, Lin TY, Chang KV, Wu WT, Özçakar L. Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials. Nutr Diabetes. 2024;14:29.
pubmed: 38755142
pmcid: 11099170
doi: 10.1038/s41387-024-00289-z
Chang T-M, Lin H-L, Tzang C-C, Liang J-A, Hsu T-C, Tzang B-S. Unraveling the Role of miR-200b-3p in Attention-Deficit/Hyperactivity Disorder (ADHD) and Its Therapeutic Potential in Spontaneously Hypertensive Rats (SHR). Biomedicines. 2024;12:144.
pubmed: 38255250
pmcid: 10813109
doi: 10.3390/biomedicines12010144
Schaffer S, Kim HW. Effects and Mechanisms of Taurine as a Therapeutic Agent. Biomol Ther (Seoul). 2018;26:225–41.
pubmed: 29631391
doi: 10.4062/biomolther.2017.251
Chapter 13: Assessing Risk of Bias Due to Missing Results in a Synthesis. https://training.cochrane.org/handbook/current/chapter-13
McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22:276–82.
pubmed: 23092060
doi: 10.11613/BM.2012.031
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
pubmed: 31462531
doi: 10.1136/bmj.l4898
Cochrane Handbook for Systematic Reviews of Interventions. Version 6.2 https://training.cochrane.org/handbook/current/chapter-10
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
pubmed: 15840177
pmcid: 1097734
doi: 10.1186/1471-2288-5-13
Chapter 6: Choosing Effect Measures and Computing Estimates of Effect https://training.cochrane.org/handbook/current/chapter-06
Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97–111.
pubmed: 26061376
doi: 10.1002/jrsm.12
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003;327:557–60.
pubmed: 12958120
pmcid: 192859
doi: 10.1136/bmj.327.7414.557
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.
pubmed: 18436948
pmcid: 2335261
doi: 10.1136/bmj.39489.470347.AD
Zaki HV, Sweed MS, Ali RM, Abdelhafeez MA. Taurine as an adjunct therapy for early left ventricular recovery in peripartum cardiomyopathy. J Obstet Anaesth Crit Care. 2021;11:9–14.
doi: 10.4103/joacc.JOACC_36_20
Sun Q, Wang B, Li Y, Sun F, Li P, Xia W, Zhou X, Li Q, Wang X, Chen J, et al. Taurine supplementation lowers blood pressure and improves vascular function in prehypertension: randomized, double-blind, placebo-controlled study. Hypertension. 2016;67:541–9.
pubmed: 26781281
doi: 10.1161/HYPERTENSIONAHA.115.06624
Spohr C, Brøns C, Winther K, Dyerberg J, Vaag A. No effect of taurine on platelet aggregation in men with a predisposition to type 2 diabetes mellitus. Platelets. 2005;16:301–5.
pubmed: 16011981
doi: 10.1080/09537100400020575
Schwarzer R, Kivaranovic D, Mandorfer M, Paternostro R, Wolrab D, Heinisch B, Reiberger T, Ferlitsch M, Gerner C, Trauner M, et al. Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. Aliment Pharmacol Ther. 2018;47:86–94.
pubmed: 29105115
doi: 10.1111/apt.14377
Sedova EM, Magnitskaia OV. A clinical experience of taurine and trimetazidine use in premenopausal women with chronic heart failure. Kardiologiia. 2010;50:62–3.
pubmed: 20144159
Roshan VD, Khalafi MK, Choobineh S. Effects of taurine supplementation on response of the cardiac injury biomarkers to bruce diagnostic protocol in patients with heart failure. Koomesh. 2011;13:73–82.
Ra SG, Choi Y, Akazawa N, Ohmori H, Maeda S. Taurine supplementation attenuates delayed increase in exercise-induced arterial stiffness. Appl Physiol Nutr Metab. 2016;41:618–23.
pubmed: 27163699
doi: 10.1139/apnm-2015-0560
Moludi J, Qaisar SA, Kadhim MM, Ahmadi Y, Davari M. Protective and therapeutic effectiveness of taurine supplementation plus low calorie diet on metabolic parameters and endothelial markers in patients with diabetes mellitus: a randomized, clinical trial. Nutr Metab (Lond). 2022;19:49.
pubmed: 35870947
doi: 10.1186/s12986-022-00684-2
Moloney MA, Casey RG, O’Donnell DH, Fitzgerald P, Thompson C, Bouchier-Hayes DJ. Two weeks taurine supplementation reverses endothelial dysfunction in young male type 1 diabetics. Diab Vasc Dis Res. 2010;7:300–10.
pubmed: 20667936
doi: 10.1177/1479164110375971
Jeejeebhoy F, Keith M, Freeman M, Barr A, McCall M, Kurian R, Mazer D, Errett L. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J. 2002;143:1092–100.
pubmed: 12075268
doi: 10.1067/mhj.2002.121927
Gordeev IG, Pokrovskaya EM, Luchinkina EE. Taurine effects on the occurrence of cardiac arrhythmias and QT interval dispersion in patients with post-infarction cardiosclerosis and chronic heart failure: a comparative randomised study. Cardiovasc Ther Prev. 2012;11:63–8.
doi: 10.15829/1728-8800-2012-1-63-68
Fujita T, Ando K, Noda H, Ito Y, Sato Y. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation. 1987;75:525–32.
pubmed: 3815764
doi: 10.1161/01.CIR.75.3.525
Esmaeili F, Maleki V, Kheirouri S, Alizadeh M. The effects of taurine supplementation on metabolic profiles, Pentosidine, soluble receptor of advanced glycation end products and methylglyoxal in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Can J Diabetes. 2021;45:39–46.
pubmed: 32861603
doi: 10.1016/j.jcjd.2020.05.004
Beyranvand MR, Khalafi MK, Roshan VD, Choobineh S, Parsa SA, Piranfar MA. Effect of taurine supplementation on exercise capacity of patients with heart failure. J Cardiol. 2011;57:333–7.
pubmed: 21334852
doi: 10.1016/j.jjcc.2011.01.007
Azuma J, Sawamura A, Awata N, Ohta H, Hamaguchi T, Harada H, Takihara K, Hasegawa H, Yamagami T, Ishiyama T, et al. Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial. Clin Cardiol. 1985;8:276–82.
pubmed: 3888464
doi: 10.1002/clc.4960080507
Azuma J, Sawamura A, Awata N, Hasegawa H, Ogura K, Harada H, Ohta H, Yamauchi K, Kishimoto S, Yamagami T, et al. Double-blind randomized crossover trial of taurine in congestive heart-failure. Curr Ther Res Clin Exp. 1983;34:543–57.
Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J. 1992;56:95–9.
pubmed: 1538580
doi: 10.1253/jcj.56.95
Averin E. Use of taurine during rehabilitation after cardiac surgery. Adv Exp Med Biol. 2015;803:637–49.
pubmed: 25833533
doi: 10.1007/978-3-319-15126-7_51
Adamchik AS, Kryuchkova IV, Ruban GM, Blagodyreva YA. New potential of pharmaceutical therapy in diastolic chronic heart failure treatment. Russ J Cardiol. 2010;01(4):40–3.
Ahmadian M, Dabidi Roshan V, Ashourpore E. Taurine supplementation improves functional capacity, myocardial oxygen consumption, and electrical activity in heart failure. J Diet Suppl. 2017;14:422–32.
pubmed: 28118062
doi: 10.1080/19390211.2016.1267059
Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000;13:3s–10s.
pubmed: 10678282
doi: 10.1016/S0895-7061(99)00252-6
Doughty RN, Whalley GA, Walsh HA, Gamble GD, López-Sendón J, Sharpe N. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation. 2004;109:201–6.
pubmed: 14707020
doi: 10.1161/01.CIR.0000108928.25690.94
Warnock R, Jeffries O, Patterson S, Waldron M. The effects of caffeine, taurine, or caffeine-taurine Coingestion on repeat-sprint cycling performance and physiological responses. Int J Sports Physiol Perform. 2017;12:1341–7.
pubmed: 28338362
doi: 10.1123/ijspp.2016-0570
Maia AR, Batista TM, Victorio JA, Clerici SP, Delbin MA, Carneiro EM, Davel AP. Taurine supplementation reduces blood pressure and prevents endothelial dysfunction and oxidative stress in post-weaning protein-restricted rats. PLoS One. 2014;9:e105851.
pubmed: 25170895
pmcid: 4149434
doi: 10.1371/journal.pone.0105851
Waldron M, Patterson SD, Tallent J, Jeffries O. The Effects of Oral Taurine on Resting Blood Pressure in Humans: a Meta-Analysis. Curr Hypertens Rep. 2018;20:81.
pubmed: 30006901
doi: 10.1007/s11906-018-0881-z
Tsimihodimos V, Gonzalez-Villalpando C, Meigs JB, Ferrannini E. Hypertension and Diabetes Mellitus. Hypertension. 2018;71:422–8.
pubmed: 29335249
doi: 10.1161/HYPERTENSIONAHA.117.10546
Kim J-H. Chapter 11 - Heart and circulatory system. In J. Y. Cho (Ed.). Recent advancements in microbial diversity. London: Academic Press; 2022. p. 229–254.
McGurk KA, Kasapi M, Ware JS. Effect of taurine administration on symptoms, severity, or clinical outcome of dilated cardiomyopathy and heart failure in humans: a systematic review. Wellcome Open Res. 2022;7:9.
pubmed: 35855073
pmcid: 9257265
doi: 10.12688/wellcomeopenres.17505.2
Mal’chikova LS, Elizarova EP. Taurine and the adenosine cyclic monophosphate levels in the heart. Kardiologiia. 1981;21:85–9.
pubmed: 6259404
Oudit GY, Trivieri MG, Khaper N, Husain T, Wilson GJ, Liu P, Sole MJ, Backx PH. Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload murine model. Circulation. 2004;109:1877–85.
pubmed: 15037530
doi: 10.1161/01.CIR.0000124229.40424.80
Takatani T, Takahashi K, Uozumi Y, Shikata E, Yamamoto Y, Ito T, Matsuda T, Schaffer SW, Fujio Y, Azuma J. Taurine inhibits apoptosis by preventing formation of the Apaf-1/caspase-9 apoptosome. Am J Physiol Cell Physiol. 2004;287:C949–53.
pubmed: 15253891
doi: 10.1152/ajpcell.00042.2004
GRAS Exemption Claim for Taurine for Use in Enhanced Water Beverages https://www.fda.gov/media/93642/download
Jacobsen JG, Smith LH. Biochemistry and physiology of taurine and taurine derivatives. Physiol Rev. 1968;48:424–511.
pubmed: 4297098
doi: 10.1152/physrev.1968.48.2.424
Nielsen CU, Bjerg M, Ulaganathan N, Holm R. Oral and intravenous pharmacokinetics of taurine in sprague-dawley rats: the influence of dose and the possible involvement of the proton-coupled amino acid transporter, PAT1, in oral taurine absorption. Physiol Rep. 2017;5:e13467.
pubmed: 29038364
pmcid: 5641942
doi: 10.14814/phy2.13467
Musazadeh V, Dehghan P, Khoshbaten M. Efficacy of omega-3-rich Camelina sativa on the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, controlled trial. Eur J Gastroenterol Hepatol. 2022;34:537–45.
pubmed: 35421019
doi: 10.1097/MEG.0000000000002297